
JNJ-67856633
CAS No. 2230273-76-2
JNJ-67856633( —— )
Catalog No. M28077 CAS No. 2230273-76-2
JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 61 | In Stock |
![]() ![]() |
5MG | 102 | In Stock |
![]() ![]() |
10MG | 170 | In Stock |
![]() ![]() |
25MG | 327 | In Stock |
![]() ![]() |
50MG | 507 | In Stock |
![]() ![]() |
100MG | 712 | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameJNJ-67856633
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis.
-
DescriptionJNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis.(In Vitro):JNJ-67856633 is effective and highly bioavailable in both mouse and rat tumors, and in some cases led to tumor stasis. JNJ-67856633 leads to potent in vivo pharmacodynamic shutdown in CD79b- as well as CARD11-mutant ABC-DLBCL models as measured by serum IL10 or uncleaved BCL10 levels in tumors.(In Vivo):Dose dependent inhibition of the generation of Tregs (CD4+CD25+FoxP3+) following CD3/28 stimulation was observed upon treatment with JNJ-67856633 suggesting a potential immune modulatory role of MALT1 inhibition.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayNF-κB
-
TargetMALT1
-
Recptorc-Myc-MAX|PARP|Apoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2230273-76-2
-
Formula Weight467.32
-
Molecular FormulaC20H11F6N5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (267.48 mM)
-
SMILESN/A
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Carabet LA, et al. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer. Eur J Med Chem. 2018 Dec 5;160:108-119.
molnova catalog



related products
-
Mepazine hydrochlori...
Mepazine hydrochloride (Pecazine hydrochloride) is a potent MALT1 inhibitor with anticancer and antitumor activities.
-
JNJ-67856633
JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric MALT1 protease inhibitor. JNJ-67856633 in some cases lead to tumor stasis.
-
MI-2
MI-2 (MALT1 inhibitor) is a selective, irreversible MALT1 paracaspase inhibitor with IC50 of 5.84 uM.